List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Overview
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Companies Involved in Therapeutics Development
B-Side Pharma Ltd
Beta Therapeutics Pty Ltd
CarboMimetics
HepaRx Ltd
Johnson & Johnson
Leadiant Biosciences Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Zucero Therapeutics Ltd
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Drug Profiles
BT-2180 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-30119 - Drug Profile
Product Description
Mechanism Of Action
H-1710 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JVB-001 - Drug Profile
Product Description
Mechanism Of Action
JVB-002 - Drug Profile
Product Description
Mechanism Of Action
JVB-003 - Drug Profile
Product Description
Mechanism Of Action
JVB-14 - Drug Profile
Product Description
Mechanism Of Action
History of Events
necuparanib - Drug Profile
Product Description
Mechanism Of Action
History of Events
pixatimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
Polysaccharides to Inhibit Heparanase for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
roneparstat - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Heparanase for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile
Product Description
Mechanism Of Action
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Dormant Products
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Discontinued Products
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Product Development Milestones
Featured News & Press Releases
Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting
Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives' Patent
Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer
Oct 29, 2013: PG545 Phase 1 Cancer Trial Update
Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics
May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by B-Side Pharma Ltd, 2022
Pipeline by Beta Therapeutics Pty Ltd, 2022
Pipeline by CarboMimetics, 2022
Pipeline by HepaRx Ltd, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Leadiant Biosciences Inc, 2022
Pipeline by Shenzhen Hepalink Pharmaceutical Group Co Ltd, 2022
Pipeline by Zucero Therapeutics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Companies Mentioned
• B-Side Pharma Ltd
• Beta Therapeutics Pty Ltd
• CarboMimetics
• HepaRx Ltd
• Johnson & Johnson
• Leadiant Biosciences Inc
• Shenzhen Hepalink Pharmaceutical Group Co Ltd
• Zucero Therapeutics Ltd